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Newly Discovered Activities for Calcitriol 
(I  ,25=-Dihydroxyvitamin D,) : Implications 
for Future Pharmacological Use 
Robert U. Simpson and Ronald Weishaar 
Summary 
Recent studies have yielded new insights 
into the critical importance of adequate 
vitamin D ,  intake and metabolism. 
Investigations of the actions of 1,25- 
dihydroxyvitamin D,  (calcitriol) on novel 
target tissues has revealed that this 
hormone has functions other than its 
recognized action in regulating blood 
calcium and phosphate levels. Reports 
have characterized calcitriol receptors 
and activities in organs and tissues as 
diverse as pancreas, skeletal and heart 
muscle, blood cells, brain, skin, pituitary, 
parathyroid, kidney, bone and intestine. 
These studies suggest functions for  
calcitriol as varied as the regulation of 
insulin and prolactin secretion, muscle 
contractility, immune cell metabolism, 
melanin synthesis and diferentiation of 
blood cells. This information may ulti- 
mately help us to understand the etiologies 
of several kinds of organ dysfunction and 
lead to the development of tissue-specific 
agents for  new therapies. 
Introduction 
Studies of the function and endocrin- 
ology of vitamin D, over the last 80 
years have elucidated the role of this 
prohormone in regulating calcium and 
phosphate concentrations in blood. 
During this period, great increases in 
our understanding of the significance of 
vitamin D have taken place. First the 
identification of the antirachitic factor 
and its importance in controlling blood 
calcium and phosphate levels was a 
major insight in basic physiology and 
had important therapeutic application. 
Secondly, studies on the metabolism of 
vitamin D led to the identification of the 
hormone, 1,25-dihydroxyvitamin D, or 
calcitriol. This discovery resulted in the 
rationale for clinical use of calcitriol in 
renal disease and increased our under- 
standing of the basic mechanisms and 
action of this steroid hormone. The 
expression of vitamin D action is now 
known to involve the functioning of 
intracellular receptors, the regulation of 
gene transcription and the translation of 
mRNA. Initially, investigators exten- 
sively characterized a specific receptor 
for 1 ,25dihydroxyvitaminD3in intestine 
and bone. Recently, calcitriol receptors 
have been characterized in tissues not 
originally recognized ascalcitriol respon- 
~ive.l-~ Subsequent in vivo and in vitro 
studies have to some extent corroborated 
receptor studies and demonstrated pre- 
viously unappreciated functions for 
calcitriol. Current data now suggest that 
1,25-dihydroxyvitamin D, affects the 
functioning of organ systems that are 
not directly responsible for regulation of 
blood calcium and phosphate. We refer 
to excellent reviews on the vitamin D 
system as sources of reference for much 
of the discussion in this text.4” It is the 
intention of this report to review the 
recent studies and summarize the in- 
formation that pertains to our expanded 
view of calcitriol for health. Our inten- 
tion is also to suggest future possible 
pharmacologically important uses for 
the vitamin D hormone. 
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Regulation of Vitamin D3 
Metabolism 
The observation that a time lag exists 
between vitamin D, administration in 
viuo and changes in bone and intes- 
tinal metabolism, together with the 
finding that vitamin D, lacks activity 
in vitro, suggested that vitamin D, 
required bioactivation to produce its 
effects. Subsequent studies established 
that a metabolite of vitamin D,, 1,25- 
dihydroxyvitamin D, (calcitriol), is the 
functionally active form of the vita- 
min, and that its metabolism is tightly 
controlled. 
The bioactivation of vitamin D, can 
be influenced by a number of factors, 
including serum calcium and phosphate 
levels, calcitriol itself, parathyroid hor- 
mone, estradiol and prolactin. Circula- 
ting levels of calcitriol are increased in 
response to reductions in serum levels of 
calcium and phosphate. This response is 
apparently mediated in part by para- 
thyroid hormone, since it has been 
shown that parathyroid hormone exerts 
a direct stimulatory effect on l-a- 
hydroxylase activity.’ In addition, para- 
thyroidectomy has been shown to blunt 
the increase in circulating calcitriol 
levels observed during lactation in 
 rat^.^-^ Estradiol and prolactin also 
stimulate the bioactivation of calcitriol, 
and the dopamine agonist bromo- 
cryptine - which decreases prolactin 
secretion - has been shown to lower 
plasma levels of calcitriol in  rat^.^-^ 
Organs involved in regulating 1,25- 
dihydroxyvitamin D, metabolism in 
vivo are illustrated in Fig. 1. 
Pharmacokinetics, 
Structure-Activity Relationships 
and ’Vitamin D Receptor 
Agonists and Antagonist’ 
Vitamin D, can enter the circulation in 
two ways. In the skin, ultraviolet light 
catalyzes the conversion of 7-keto- 
cholesterol to pre-vitamin D,, which 
then thermally equilibrates to vitamin 
D,. Vitamin D, is also readily absorbed 
from the small intestine. Vitamin D, and 
its metabolites are transported in the 
circulation bound to a 52,000 molecular 
weight protein which has been termed 
the serum vitamin D binding 
Like vitamin D,, calcitriol is also 
orally active, and absorption occurs in 
the proximal portion of the small 
intestine. The absorption of calcitriol 
appears to require complex formation 
with bile salts, and such absorption can 
be impaired by biliary cirrhosis. Studies 
have demonstrated that when given 
Vitamin D, + Pre-vitamin D + 7-keto-cholesterol 
25(OH) vitamin D3 v 
Fig. 1. Organs involved in metabolism of vitamin D.  
chronically via oral administration, 25 
hydroxyvitamin D, is more effective 
than calcitriol for maintaining serum 
calcium and in promoting bone miner- 
alization. These observations likely 
indicate that calcitriol is subject to rapid 
inactivation or elimination; an im- 
portant consideration when attempting 
to develop useful therapeutic agents 
which act as ‘vitamin D agonists’. In 
this regard, it has been shown that 
fluorination of calcitriol to produce 
24,24-difluoro-calcitriol increased the 
biopotency and serum half-life of this 
analogue.* It has also been reported that 
1-fluoro-vitamin D, possesses a selective 
stimulatory effect on bone calcium 
mobilization, compared to intestinal 
calcium tran~port .~ 
A number of analogs of calcitriol 
have been evaluated for biological 
activity and/or therapeutic utility. 
Several recent studies have employed 
competitive binding experiments to 
identify structural features which en- 
hance the activity of various vitamin D, 
congeners as calcitriol receptor agonists. 
For such studies the ability of these 
congeners to compete with [3H]calcitriol 
for binding sites on the intracellular 
receptor binding protein is evaluated. 
Such experiments have demonstrated 
that the 1-a-OH group contributes 
substantially to the potency of vitamin 
D,. Activity is also enhanced consider- 
ably by the presence of a 25-OH group, 
with calcitriol being 100 to 1,000-fold 
more potent than la-hydroxyvitamin 
D,. The presence of two adjacent 
hydroxyl groups, e.g. 1,24R-25-tri- 
hydroxyvitamin D,, impairs interaction 
with the vitamin D receptor, and lowers 
potency. Structural considerations for 
vitamin D, metabolites and synthetic 
vitamin D analogues have been described 
in detail by Stern6 
To date, no compound has been iden- 
tified which exerts a classic antagonist 
effect (high-affinity binding, no intrinsic 
activity) on the intracellular vitamin D 
receptor. However, a number of agents 
have been shown to impair calcitriol 
synthesis and may, therefore, be con- 
sidered to ‘antagonize’ the response to 
vitamin D,. Such agents include inhibi- 
tors of 25-hydroxylase such as 24-nor- 
25-hydroxy vitamin D,, which also lacks 
intrinsic vitamin D receptor ‘agonist’ 
a~tivity.*-~ Several metabolites of vita- 
min D, have been shown to inhibit 1- 
a-hydroxylase activity; however, these 
metabolites also possessed intrinsic re- 
ceptor ‘agonist’ a~ t iv i ty .~ -~  
I ntest i ne 
Our greatest understanding of the 
mechanism of action of calcitriol on 
subcellular processes comes from studies 
of its effects on the intestine. Vitamin D, 
acting via its metabolite, calcitriol, 
stimulates Ca2+ transport from the 
lumen of the intestine through the cell 
and into the blood. Along with the 
intestinal transport of Ca2+, calcitriol 
stimulates the transport of PO,2- from 
intestinal lumen to b l o ~ d . ~ - ~  It is now 
recognized that calcitriol induces the 
synthesis of a cytosolic CaBP.l0 This 
action most likely does not account for 
all the processes activated by calcitriol 
and required for calcium transport 
across the intestinal epithelia. There- 
fore, many studies have concerned them- 
selves with identifying other proteins or 
factors that are synthesized in intestine 
and under the control of calcitriol. For 
example, a membrane-bound calcium- 
binding protein complex possessing 
phosphatase activity has been reported 
to be under the direct control of vitamin 
D.” A different mechanism of action - 
alteration of membrane phospholipid 
composition - for calcitriol has been 
supported by Rasmussen and co- 
workers.12 These data suggest that the 
activity of calcitriol might not be 
explained entirely by the activation of 
nuclear transcription of specific genes. 
Clearly, much work remains to be done 
before a clear understanding of how 
calcitriol affects intestinal cell processes 
is reached. 
Osteoporosis 
Vitamin D-dependent rickets was cured 
with the therapeutic application of the 
anti-ricket factor vitamin D. Recently, it 
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was also shown that calcitriol is of great 
therapeutic use in treatment of such 
diseasesasrenal osteodystrophy, vitamin 
D-resistant rickets due to an inborn 
error of vitamin D metabolism, and 
certain hypoparathyroid  disorder^.^" 
Osteoporosis is an age-related disorder 
that affects over 15 million persons in 
the United States. The bone wasting 
associated with this disease suggests the 
possible therapeutic usefulness of calci- 
trio1 for the treatment of osteoporosis. 
Initial clinical studies focused on the 
action of the prohormone, vitamin D, 
on postmenopausal osteopor~sis .~~ 
These studies did not demonstrate a 
therapeutic use of vitamin D for 
treatment of osteoporosis. It has been 
argued that use of vitamin D for the 
treatment of postmenopausal osteo- 
porosis has not been effective due to 
decreased metabolism of vitamin D to 
the active metabolite calcitriol in the 
aged.14 Analysis of serum calcitriol 
supports this contention, showing that 
postmenopausal women have a signifi- 
cant decrease in serum calcitriol levels. 
Studies using 0.25 pg calcitriol showed 
that calcitriol was ineffective in treating 
this disease.15 Others, however, using 
higher concentrations of calcitriol, have 
demonstrated significant improvement 
of bone parameters in osteoporetic 
patients.I6 Further clinical testing of 
calcitriol for the treatment of postmeno- 
pausal osteoporosis is on-going and 
essential for establishing the therapeutic 
usefulness of calcitriol. 
Kidney 
A major action of calcitriol is to regu- 
late renal 25-hydroxyvitamin D,-l-a- 
hydroxylase (la(0H)ase). It has been 
shown that calcitriol brings about a 
suppression of la(0H)ase concomitant 
with an increase in 25-hydroxyvitamin 
D3-24-hydroxylase (24(OH)ase). These 
observations have been supported by in 
vivo and in vitro This action 
of calcitriol is analogous to the action of 
other steroid hormones to effect a 
feedback inhibition of their synthesis. 
The feedback inhibition of la(0H)ase is 
dependent on blood calcium concentra- 
tions since it has been observed that 
calcitriol will, in fact, stimulate its own 
synthesis in hypocalcemic animals. 
Possible actions of calcitriol on renal 
calcium and phosphate handling are not 
at present fully characterized. Studies 
have shown that vitamin D increases 
renal retention of calcium. Also, it has 
been shown that vitamin D increases 
renal absorption of phosphate. How- 
ever, these in viuo studies could not 
eliminate the possible secondary action 
of other renal active agents to elicit 
these effects. In spite of this, calcitriol 
receptors have been demonstrated in 
distal renal tubule cells, cultured kidney 
cells and kidney h~mogena te s .~ -~  
Further evidence that calcitriol has a 
direct effect on kidney functions comes 
in the data showing that a specific 
vitamin D-dependent calcium-binding 
protein is present in kidney tubule cells. 
Vitamin D and Skeletal Muscle 
Several authors have suggested a poten- 
tial role for vitamin D in the regulation 
of skeletal muscle contractile function. 
Such involvement is based upon the 
observation that vitamin D deficiency is 
associated with skeletal muscle myo- 
pathy and muscle fibre atrophy, condi- 
tions which are reversible upon adminis- 
tration of vitamin D or its metab01ites.l~ 
In addition, Curry et al. have shown 
that the rate of calcium uptake by skele- 
tal muscle sarcoplasmic reticulum isola- 
ted from vitamin D-deficient rabbits 
is significantly reduced compared with 
that of sarcoplasmic reticulum isolated 
from normal rabbits.'* This reduction 
is apparently not related to any change 
in the ATPase activity of the sarco- 
plasmic reticulum. We reported that 
receptors for calcitriol exist in skeletal 
muscle myoblasts and at significantly 
lower concentrations in excised muscle 
tissue.lg Others have demonstrated that 
calcitriol stimulated calcium transport 
in cultured muscle myoblasts.20 A pos- 
sible dihydroxyvitamin 1,25D, specific 
effect on muscle myoblasts is currently 
being studied in our laboratory. 
In a recent study, Wassner and 
co-workers reported that weight gain 
and skeletal muscle mass were reduced 
in vitamin D-deficient rats, and that 
myofibrillar protein degradation was 
increased.21 According to the authors, 
these changes were associated with the 
onset of hypocalcemia and could be 
reversed by the addition of vitamin D to 
the diet or by feeding the vitamin 
D-deficient rats diets that contained 
sufficient quantities of calcium to restore 
circulating calcium to normal levels. 
Thus, although vitamin D repletion 
leads to improved muscle protein ana- 
bolism and an increase in skeletal 
muscle mass and weight gain, these 
effects have yet to be proved to be a 
result of the direct action of vitamin D 
or a vitamin D-derived metabolite on 
skeletal muscle. 
Recent discoveries Well- 
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Fig. 2. Target tissues for calcitriol. 
Vitamin D and Cardiac Muscle 
It has been known for many years that 
administration of pharmacological 
quantities of vitamin D can produce 
myocardial failure, presumably due to 
hypercalcemia and calcification of car- 
diac muscle. Such hypercalcemia can 
persist for months following discon- 
tinuation of vitamin D administration. 
Furthermore, vitamin D has been 
reported to alter the ultra-structure of 
cardiac muscle endoplasmic 
A physiological role for vitamin D in 
influencing myocardial calcium homeo- 
stasis has been suggested by the recent 
observation of Simpson et al. that 
cardiac cells grown in culture contain a 
specific receptor for ~alcitriol.~, This 
receptor has also been identified in 
whole left ventricular muscle from 
adult rats. In addition, Thomassett 
and co-workers have shown that the 
10K vitamin Ddependent calcium- 
binding protein, but not the 28K 
calcium binding protein, is present in rat 
heart muscle.24 The relevance of this 
latter observation is not known at the 
present time. 
Receptors for calcitriol have also 
been identified in uterine muscle.25 
Cancer Cells 
The initial observation that cancer cells 
possess calcitriol receptors was that of 
Eisman and collaborators.2e Since this 
report, a number of malignant tumors 
and cell lines have been characterized as 
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possessing calcitriol receptors. Further- 
more, calcitriol has been shown to 
inhibit proliferation of breast and 
melanoma cell lines and to initiate 
terminal differentiation of myeloid 
leukemia cells.27 
Possible clinical usefulness of calci- 
triol for control of certain malignant 
cancers was supported by studies that 
correlated 1,25-dihydroxyvitamin D, 
receptor concentrations and potency 
of supra-physiological levels of 1,25- 
dihydroxyvitamin D, action to inhibit 
cancer cell proliferation.28 Further- 
more, it has been shown that survival 
time of mice injected with leukemia cells 
was greater in animals dosed with calci- 
triol than control mice.29 Obvious dis- 
advantages are present in the use of 
calcitriol for control of endocrine-as- 
sociated malignancies. Hypercalcemia 
and bone wasting induced by this agent 
would be prevalent side-effects. How- 
ever, the use of calcitriol in concert 
with hypocalcemic agents (e.g. diphos- 
phonates, glucocorticoids) may prove 
useful. Future development of vitamin 
D analogs that possess cancer-inhibitory 
activities but are devoid of calcium- 
mobilizing actions may permit thera- 
peutic application of calcitriol. 
The observations that calcitriol recep- 
tors exist in leukemia cells and that 
calcitriol stimulates differentiation of 
these cells into mature monocytes 
suggests that the hormone may be 
involved in the regulation of monocyte 
differentiation. Recently, this work has 
been extended to show that calcitriol 
stimulates the aggregation of precursor 
cells into poly-nuclear osteoclastic-like 
cells. This process was suggested as a 
possible mechanism for calcitriol- 
induced osteoclastic bone reabsorption. 
Receptors for calcitriol have also been 
characterized in activated T cells.30 
Therefore, a function for calcitriol in the 
immune response may exist. 
Skin, Brain and Sex Tissue 
Calcitriol receptors have been demon- 
strated in mammary and skin 
A possible role of calcitriol in calcium 
handling by skin, sweat glands and 
mammary glands is suggested. However, 
little data on hormone action have been 
presented. An increase in 7-dehydro- 
cholesterol levels in skin due to calcitriol 
has been identified. This suggests that 
calcitriol may have a feedback-inhibi- 
tory action on the synthesis of vitamin 
D, in skin (see ref. 3 for review). 
Recently, Hosoi et al. demonstrated 
that calcitriol exerted a time- and 
dose-dependent stimulatory effect on 
melanin synthesis in B16 mouse mela- 
noma cells.31 This stimulatory effect was 
apparently the result of an increase in 
the activity of tyrosinase, a key enzyme 
involved in regulating melanin synthesis. 
According to the authors, since pig- 
mentation of the skin prevents the 
penetration of sunlight to the dermis, 
stimulation of melanin synthesis by 
calcitriol may represent a negative feed- 
back mechanism for suppressing the 
conversion of pre-vitamin D, to 
vitamin D,. 
The existence of a brain-pituitary axis 
for calcitriol effects was suggested by 
autoradiographic studies of Stumpf et 
al.32 Specific localization of [3H]calcitriol 
in neurons of rat forebrain, hindbrain 
and spinal cord was demonstrated. 
Receptors have also been identified for 
calcitriol in ovaries and testes; however 
no clear functional role for calcitriol in 
these tissues has as yet been 
identified.1-3. 33 
Exocrine Function of Calcitriol 
The presence of calcitriol receptors in 
parathyroid, pancreas, testes, ovaries 
and pituitary has raised the possibility 
of a direct action of this hormone in the 
regulation of hormone synthesis and 
secretion. We will review the data 
presented to support a functional role of 
calcitriol in exocrine cell processes. 
Pancreas 
Recent studies have provided evidence 
that vitamin D plays a role in regulating 
pancreatic metabolism. Such an involve- 
ment is supported by several obserya- 
tions, including the presence of a 
receptor for calcitriol in the pancreas, 
and of a vitamin D-dependent calcium- 
binding protein (CaBP).34-35 Kadowaki 
and Norman have shown that the pan- 
creatic CaBP is homologous with the 
intestinal CaBP.5 In addition, changes 
in dietary calcium and phosphorus, as 
well as changes in circulating levels of 
calcitriol, produce comparable changes 
in pancreatic and intestinal CaBP levels 
(for review see ref. 5) .  
In 1980, Norman and co-workers 
demonstrated that vitamin D deficiency 
inhibited insulin secretion from the 
perfused pancreas, whereas vitamin D 
repletion improved insulin ~ecretion.,~ 
An involvement of vitamin D with 
insulin secretion is also implicated by 
the observation that although pancreatic 
levels of CaBP are low compared with 
levels in the intestine or the kidney, 
pancreatic CaBP is present exclusively 
in the B-cek5 Together these observa- 
tions imply a physiological role for 
vitamin D in modulating calcium 
metabolism in the pancreas, and indicate 
that vitamin D may exert an influence 
on insulin secretion as well. However, 
vitamin D deficiency also leads to de- 
creased food intake and hypocalcemia. 
The direct action of calcitriol on insulin 
secretion therefore remains to be firmly 
established. 
Parathyroid 
There is in vivo and in vitro evidence to 
support a direct action of calcitriol in 
regulating secretion of parathyroid hor- 
mone (PTH) from the parathyroid 
gland. Evidence has been presented 
showing that a calcitriol receptor exists 
in excised parathyroid tissue from avian 
and mammalian species.34 Furthermore, 
immunochemical vitamin D-dependent 
CaBP have been localized to the 
p a r a t h y r ~ i d . ~ ~  Functional studies have 
suggested that calcitriol in normal 
calcemia can suppress the secretion of 
PTH. However, in vitro studies designed 
to demonstrate a direct action of 
calcitriol on parathyroid tissue have 
yielded ambiguous data. It has been 
shown that calcitriol inhibited, stimu- 
lated or had no effect on release of PTH 
from parathyroid cells dosed in vitro (for 
review see ref. 3). These discrepancies 
in results might be explained by the 
nutritional status of tested animals or in 
terms of the in vitro incubation con- 
ditions for PTH release. Recent studies, 
however, do support an in uiuo role 
for calcitriol in regulation of PTH 
 secretion^.^' 
Pituitary 
Pituitary cells have been shown to 
possess specific calcitriol receptors and 
the vitamin D-dependent calcium- 
binding protein.l* 34 It has recently been 
shown that calcitriol has a specific and 
selective action to increase prolactin 
synthesis and secretion from pituitary 
cells.38 This has been shown measuring 
the peptide and specific mRNAs 
for prolactin. The effect of 1,25-dihy- 
droxyvitamin D, on prolactin mRNA 
synthesis was diminished in low- 
calcium-containing media. These find- 
ings demonstrate that calcitriol stimu- 
lates prolactin gene expression and that 
calcium is involved in this expression. 
In addition, autoradiography and im- 
munohistochemistry techniques have 
provided evidence that calcitriol specifi- 
cally localizes in those cells that 
secrete thyroid-stimulating hormone.39 
These data indirectly suggest that calci- 
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triol may modulate thyroid hormone 
secretion. 
The presence of receptors for calcitriol 
in exocrine tissues suggests a functional 
role for calcitriol in endocrine-controlled 
processes. However, with the exception 
of the action of calcitriol on PTH 
secretion, aclear picture of the regulation 
of hormone secretion by calcitriol 
remains to be established, and further 
studies are required to translate in vitro 
observations of calcitriol secretory con- 
trol to in viva relevance. 
Conclusions 
During the last two decades the im- 
portant role of calcitriol in regulating 
bone mineralization and intestinal 
calcium transport has been well docu- 
mented. Moreover, the ability of calci- 
triol to treat renal osteodystrophy has 
been firmly established. In addition, 
clinical studies are currently under way 
that are aimed at demonstrating the 
ability of calcitriol to prevent the onset 
or retard the progression of osteo- 
porosis. 
Several recent studies have shown 
that in addition to its effect on bone, 
intestine and kidney metabolism, calci- 
triol may play an important role in 
regulating key metabolic processes in a 
number of other organs and cells, 
including pancreas, skin, cancer cells, 
cardiac and skeletal muscle, brain, para- 
thyroid gland, testes and ovaries. These 
processes include insulin secretion, 
muscle contractility, cell differentiation 
and melanin synthesis. Such discoveries 
have prompted interest in the potential 
utility of vitamin D receptor agonists 
and antagonists, and agents which may 
influence 1,25-dihydroxyvitamin D, 
action as potential therapeutic agents 
for the treatment of diabetes, cancer, 
muscle myopathy, and other patho- 
logical conditions. Although there exists 
a paucity of such compounds, the 
tissue-selective effects of an analog of 
vitamin D indicate that it may be 
possible to design agents which limit the 
potent hypercalcemic effect of 1,25- 
dihydroxyvitamin D,. If made available, 
tissue-specific calcitriol agonists and 
antagonists may provide useful thera- 
peutic agents for novel treatment of 
endocrine diseases. 
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Human choriogonadotropin, a hormone 
derived from the syncytiotrophoblast 
cells of the placenta, is a member of the 
glycoprotein hormone family which also 
contains the pituitary hormones lutropin, 
follitropin and thyrotropin. These four 
hormones are comprised of two dissimilar 
subunits, one (a) being common to all four 
and the other (J) conferring hormonal 
specificity. Information is rapidly accum- 
ulating on rhe nature and regulation of the 
genes for these subunits, as well as the 
structural aspects, mechanism-of-action 
and physiological roles of these complex 
hormones. This mini review considers 
some of the recent advances in our 
understanding of human choriogonado- 
tropin. 
The Glycoprotein Hormones 
There are four characterized members 
of the human (h) glycoprotein hormone 
family : choriogonadotropin (CG, gener- 
ally designated as hCG), lutropin (LH, 
luteinizing hormone), follitropin (FSH, 
follicle-stimulating hormone) and thyro- 
tropin (TSH, thyroid-stimulating hor- 
mone). hCG is a product of the syn- 
cytiotrophoblast cells of the placenta, 
and the other hormones are synthes- 
ized in and secreted by specific cell types 
of the adenohypophysis (i.e. the anterior 
lobe of the pituitary). There has also 
been a suggestion of an hCG-like 
material in human pituitary, and hCG 
and subunits are secreted by certain 
tumors. Each hormone contains a com- 
mon a subunit and hormone-specific 
B subunit; only the a/3 complex (Fig. 1) 
exhibits significant biological activity. 
Vitamin D stimulates prolactin synthesis by 
GH,C cells incubated in chemically defined 
medium. Endocrinology 111, 1755-1757. 
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hCG exhibits LH-like effects and is corpus luteum and stimulation of prog- 
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Fig. 1. Schematic representation of the reversible formation of hCG from the constituent subunits; the Kd 
is about 0.1 p ~ .  The a subunit is common to the four human glycoprotein hormones, and the p subunit 
confers hormonal specificity. Characteristics of the a and p subunits and the ap dimer are provided. Mr(P), 
Mr(C) and M,(t) denote the respective molecular weights ( K  = kilodaltons) of the polypeptide portion, 
the carbohydrate (CHO) portions (the subunits are heterogenous, and the values given are averages) and 
the total (i.e. polypeptide plus carbohydrate). The number of amino acid residues (Res), disulfides (S-S), 
N-linked oligosaccharides (N-c) and 0-linked oligosaccharides (0-0 are also given. The disulfide pairings 
are controversial, but there is general agreement of disulfide b o n h  between half-cystines 7-31 and 1&32 
in the a-subunit and between 23-72,26110 and 93-100 in the$ subunit. Additional information is provided 
in refs. 4-6. 
